8-K: Cardinal Health Exceeds Expectations with Strong Q4 and Fiscal Year 2024 Results, Raises 2025 Guidance

Cardinal Health reports a 12% increase in fourth-quarter revenue and raises its fiscal year 2025 non-GAAP EPS guidance, driven by strong performance in key segments.

Summary

• Cardinal Health's fourth-quarter revenue reached $59.9 billion, a 12% increase year-over-year.
• GAAP operating earnings for the quarter were $401 million, with a GAAP diluted EPS of $0.96.
• Non-GAAP operating earnings increased by 14% to $605 million, and non-GAAP diluted EPS rose by 29% to $1.84.
• Fiscal year 2024 revenue totaled $226.8 billion, an 11% increase from the previous year.
• The company's fiscal year 2024 operating cash flow and adjusted free cash flow hit record highs of $3.8 billion and $3.9 billion, respectively.
• Non-GAAP diluted EPS for fiscal year 2024 was $7.53, a 29% increase year-over-year.
• Cardinal Health has raised its fiscal year 2025 non-GAAP EPS guidance to a range of $7.55 to $7.70, up from at least $7.50.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, increased guidance, and strategic initiatives. The company's performance exceeded expectations, and management expressed confidence in future growth. However, there are some risks and challenges mentioned, which temper the overall sentiment slightly.

Positives

• Cardinal Health experienced strong revenue growth in both the fourth quarter and the full fiscal year.
• The company's non-GAAP earnings per share saw significant increases, indicating improved profitability.
• Record cash flow generation highlights the company's financial strength.
• The raised fiscal year 2025 guidance demonstrates management's confidence in future performance.
• The Pharmaceutical and Specialty Solutions segment showed solid profit growth.
• The Global Medical Products and Distribution segment showed significant profit improvement.
• The company is actively working to improve shareholder value through its GMPD Improvement Plan.
• Increased share repurchases indicate a commitment to returning value to shareholders.
• The company has formed a joint venture with CVS Health, Averon, to increase access to lower cost specialty pharmaceuticals.
• Cardinal Health has entered into a 5-year distribution agreement with Publix.

Negatives

• GAAP operating earnings and diluted EPS were lower than non-GAAP figures due to various adjustments.
• The company experienced a $39 billion revenue headwind due to the OptumRx contract expiration.
• The Pharmaceutical and Specialty Solutions segment is expected to see a 4% to 6% revenue decline in fiscal year 2025.
• The company recorded a $675 million pre-tax goodwill impairment charge related to GMPD in fiscal year 2024.

Risks

• The company faces risks related to achieving its strategic objectives, including the execution of the GMPD Improvement Plan.
• Competitive pressures in various lines of business could impact revenue and profitability.
• The performance of the generics program and the ability to offset generic deflation are ongoing concerns.
• Risks associated with the distribution of opioids, including financial impacts from settlements and ongoing investigations, could affect results.
• Ongoing audits with the IRS could lead to an increase in the effective tax rate or other costs.
• Litigation matters, including a Department of Justice investigation, pose potential risks.
• Uncertainties associated with the pricing of branded pharmaceuticals could impact financial performance.
• The At-Home unit goodwill could become impaired due to changes in the long-term financial plan or other factors.

Future Outlook

Cardinal Health raised its fiscal year 2025 non-GAAP EPS guidance to $7.55 to $7.70 and updated its Pharmaceutical and Specialty Solutions segment profit growth outlook to 1% to 3%. The company also improved its fiscal year 2025 outlooks for Interest and other, diluted weighted average shares outstanding and share repurchases.

Management Comments

• Jason Hollar, CEO of Cardinal Health, stated that fiscal 2024 marked a year of strong operational execution and record financial results.
• He also mentioned that the company delivered robust cash flow generation, continued profit growth in the Pharmaceutical and Specialty Solutions segment, and significant improvement driven by the GMPD Improvement Plan.
• Hollar noted that the company enters the new fiscal year with momentum and confidence, evidenced by the raised fiscal year 2025 guidance.

Industry Context

This announcement reflects Cardinal Health's efforts to navigate a complex healthcare landscape, focusing on operational improvements and strategic growth. The joint venture with CVS Health and the distribution agreement with Publix highlight the company's focus on expanding its reach and offerings. The company is also investing in new facilities to support the complex handling requirements of cell and gene therapies.

Comparison to Industry Standards

• Cardinal Health's revenue growth of 11% for fiscal year 2024 is strong compared to some of its peers in the pharmaceutical distribution industry, such as McKesson and AmerisourceBergen, which have seen more modest growth in recent periods.
• The 29% increase in non-GAAP diluted EPS for both the fourth quarter and the full fiscal year is a significant achievement, indicating strong operational efficiency and cost management compared to industry averages.
• The company's focus on improving the Global Medical Products and Distribution segment is a key differentiator, as this segment has faced challenges in recent years for many companies in the sector.
• The raised fiscal year 2025 guidance suggests a positive outlook, which is notable given the ongoing challenges in the healthcare supply chain and pharmaceutical pricing.
• The company's adjusted free cash flow of $3.9 billion is a strong indicator of financial health and is higher than many of its competitors, allowing for strategic investments and shareholder returns.

Legal Proceedings

• The company is subject to ongoing risks associated with the distribution of opioids, including the financial impact associated with settlements with governmental authorities.
• There are ongoing Department of Justice Investigations related to the company's anti-diversion program.
• The company is facing risks arising from ongoing audits with the IRS.
• There is a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders will benefit from increased share repurchases and the potential for higher returns due to improved financial performance.
• Employees may experience positive impacts from the company's growth and strategic initiatives.
• Customers will benefit from the company's focus on innovation and improved service delivery.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors may view the company as a lower risk due to its strong financial performance and cash flow.

Next Steps

• Cardinal Health will continue to execute its GMPD Improvement Plan.
• The company will focus on achieving its fiscal year 2026 target of approximately $300 million in segment profit for GMPD.
• The company will pursue further simplification actions and working capital improvements to create at least $500 million in near-term value from GMPD by fiscal year 2026.
• Cardinal Health will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024.
• Cardinal Health will participate in the Baird 2024 Global Healthcare Conference on September 10, 2024.

Key Dates

Keywords

Cardinal Health, Pharmaceuticals, Medical Products, Distribution, Financial Results, Earnings, Revenue, EPS, Guidance, Cash Flow, GMPD, Share Repurchase, Healthcare